Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with major depressive disorder (MDD).  In 2020, Neurocrine Biosciences and Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline, including an exclusive license to NBI-1065845 (TAK-653). The study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsberg Depression Rating Scale (MADRS) total score at both Day 28 (primary) and Day 56 (secondary).  In the full analysis data set, the least squares (LS) mean differences from baseline in MADRS ...